Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
Our new In the Zone on targeted MS imaging is now live! Check it out!

Poster: Comparative metabolomics analysis of prostate cancer cells with different ethnic and tumorigenic phenotypes (Waters Corporation)

7 Oct 2014
General interest

A comprehensive high-throughput lipidomics and metabolomics analysis of prostate cancer cells with different tumorigenic phenotypes reveal potential markers for aggressive disease.

Click here to view poster

Related Links

  • Waters Corporation

Top content

  • Accidental discovery: SwRI scientists stumble upon a chromatography game-changer
  • Culture medium analysis solutions
  • SPACs and the race to cell and gene therapy breakthrough

Related tags

cancer high-throughput metabolomics
Previous article Next article

Related articles

12 FEB 2015 CLINICAL
Researchers design nicotine vaccine that demonstrates significant immune response
20 JUN 2014 GENERAL INTEREST
The importance of experimental design and QC samples in large-scale and MS-driven untargeted metabolomic studies of humans
5 OCT 2017 NEWS
Blood samples could be stronger alternatives to biopsies in the prediction of response rate to immunotherapy
24 JUN 2015 CLINICAL
Potential metastasis indicator discovered in blood samples
29 OCT 2020 BIOMARKERS
Biomarkers identified for screening and potentially treating patients with COVID-19
6 JUL 2020 GENERAL INTEREST
The latest metabolomics developments: an interview with Martin Giera
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone